|
May 26
|
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer
|
|
May 26
|
Gilead’s Phase III trial for breast cancer therapy meets primary goal
|
|
May 24
|
Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump
|
|
May 24
|
Gilead announces ASCENT-03 study meets primary endpoint
|
|
May 23
|
Gilead Sciences (NasdaqGS:GILD) Announces Promising Phase 3 Results For Trodelvy In Breast Cancer
|
|
May 23
|
Gilead (GILD) to Acquire HOOK for $10 million
|
|
May 23
|
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
|
|
Apr 11
|
How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs
|
|
Apr 10
|
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
|
|
Apr 10
|
PatientView Ranks Gilead "Best" at ESG
|
|
Apr 9
|
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
|
|
Apr 9
|
Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1
|
|
Apr 9
|
2 Top Dividend Stocks That Could Set You Up for Life
|
|
Apr 8
|
Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections
|
|
Apr 7
|
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
|
|
Mar 14
|
Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?
|
|
Mar 13
|
Why Gilead Sciences, Inc. (GILD) is the Best Pharma Stock to Buy According to Hedge Funds
|
|
Mar 13
|
GILD vs. VRTX: Which Stock Is the Better Value Option?
|
|
Mar 13
|
Gilead (GILD) Up 10.3% Since Last Earnings Report: Can It Continue?
|
|
Mar 13
|
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
|